StockData

Actinium Pharmaceuticals vs Vyome

ATNM and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ATNM and HIND compare

Actinium Pharmaceuticals is the larger company, worth 4.4 times as much as Vyome ($46.8M against $10.7M).

Actinium Pharmaceuticals scores higher on the StockData Score (10 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATNMHIND
Size and price
Market cap$46.8M$10.7M
Share price$1.49$1.53
Change, 1 year19.2%−69.0%
Change, 5 years−79.6%−100.0%
Beta (5Y)1.261.61
Employees2518
StockData Score
Total score10 (better)1
Valuation score4 (better)0
Growth score00
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/E4.1×–
P/S–82.8×
P/B1.5×–
EV/EBITDA1.1×–
Fair value$7.21–
Margin of safety79.3%–
Growth
Revenue growth (TTM)–−67.1%
Revenue growth, 5Y average–−51.0%
Profitability
Gross margin–52.7%
Operating margin–−9190%
Net margin–−8717%
Return on equity45.9% (better)−194%
Return on invested capital–−173%
Financial health
Debt / equity0.00–
Interest coverage–−285.8×
Current ratio4.084.37 (better)
Altman Z-score−9.02 (better)−13.61
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield–40.0%
Shareholder yield0.00%40.0% (better)
Ownership
Held by institutions16.8%2.0%
Held by insiders5.9%6.8%
Short interest, % of float2.0%0.28%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.